Comparative Pharmacology
Head-to-head clinical analysis: RYBELSUS versus TANZEUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RYBELSUS versus TANZEUM.
RYBELSUS vs TANZEUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Tanzeum (albiglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Initial: 3 mg orally once daily for 30 days; then increase to 7 mg orally once daily. If additional glycemic control needed, may increase to 14 mg orally once daily after at least 30 days on 7 mg.
Subcutaneous injection: 300 mg every 4 weeks. Administer as 3 consecutive injections of 100 mg each in the same body region (abdomen, thigh, or upper arm).
None Documented
None Documented
Terminal elimination half-life is approximately 1 week (168 hours) after multiple doses due to absorption-rate-limited elimination. This supports once-weekly dosing, with steady state reached after 4-5 weeks.
Terminal elimination half-life approximately 5 days (range 4-6 days), supporting weekly subcutaneous dosing
Primarily eliminated via degradation by general proteolysis; intact peptide is not excreted renally or hepatobiliary. The degradation products are eliminated via renal and fecal routes. Approximately 60-70% of the dose is recovered in urine (as metabolites) and 30-40% in feces (as metabolites).
Renal (79% as unchanged drug), biliary/fecal (minor, ~1%)
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist